Acumen to Stop Sabirnetug Development After Phase 2 Trial Failure
Acumen Pharmaceuticals said it plans to stop development of sabirnetug following a failed Phase 2 trial.
Acumen Pharmaceuticals said it plans to stop development of sabirnetug following a failed Phase 2 trial.